摘要:
The present invention relates to compounds of formula la: and pharmaceutically acceptable salts thereof. The thieno[3,2-d]pyrimidine, thieno[2,3-d]pyrimidine, thieno[3,2-b]pyridine, thieno[2,3-b]pyridine, and pyrrolo[2,3-d]pyrimidine compounds selectively inhibit B-Raf kinase activity and are useful for treating disorders mediated by B-Raf kinase, and for the treatment of cancer.
摘要:
This invention is directed to compounds of formula (I): wherein R1, R2, X, and n are as defined herein, including all crystalline forms and pharmaceutically acceptable salts thereof, with the provisos that when X is CH2, n is 1, and R1 is —COOH, then R2 cannot be wherein A is CH3—, CH3CH2— or a haloalkyl of 1 to 2 carbon atoms, and B is a halogen; and when X is CH2, n is 2, and R1 is —COOH, then R2 cannot be The invention is also directed to compositions containing compounds of the invention and methods of using the compounds to treat or prevent hepatitis C virus infections.
摘要:
The invention is directed to a method of treating, preventing, or inhibiting a Hepatitis C viral infection in a mammal comprising contacting the mammal with an effective amount of a compound of the formula: wherein substitutions at R1-R13, m and Y are set forth in the specification.
摘要翻译:本发明涉及一种治疗,预防或抑制哺乳动物中丙型肝炎病毒感染的方法,包括使哺乳动物与有效量的下式化合物接触:其中R 1 - R 13,m和Y在说明书中列出。
摘要:
The invention is directed to methods of treating, preventing, or inhibiting a Hepatitis C viral infection in a mammal comprising contacting the mammal with an effective amount of a compound of the formula: Wherein substitutions at R1, R2, R3—R12, and Y are set forth in the specification.
摘要:
This invention provides compounds of Formula I, having the structure: that are useful in treating diseases or disorders mediated by TNF-α. The invention further provides methods for use of the compounds for treating such a disease or disorder or for alleviating symptoms thereof.
摘要:
The invention is directed to a method of treating, preventing, or inhibiting a Hepatitis C viral infection in a mammal comprising contacting the mammal with an effective amount of a compound of the formula: wherein substitutions at R1-R13, m and Y are set forth in the specification.